ONCASPAR Helps You Reach for What’s Possible

An acute lymphoblastic leukemia patient wearing a bandana over her hair flexes her bicep.

Remission that’s within reach

99% of people with B-cell ALL achieved complete remission after being treated with a chemotherapy regimen that included ONCASPAR

99% of people with B-cell ALL achieved complete remission

Pegaspargase (ONCASPAR) is included in first-line ALL treatment regimens recommended by the National Comprehensive Cancer Network® (NCCN®).*,† Since being introduced in 1994, it has helped many thousands of people with ALL and has given families hope for a future they can look forward to.

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 10, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

†Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Acute Lymphoblastic Leukemia V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed April 3, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.

With ONCASPAR, living disease free is a real possibility

Minimal residual disease (MRD) means that a small number of cancer cells are still present in the bone marrow after ALL has been treated. Even if a patient is in remission, there is a possibility that ALL might come back if treatment is discontinued. That’s why it is important for patients to remain on the treatment outlined by their healthcare professional.

MRD negativity means that no cancer cells were found after using sensitive tests. Sensitive tests that look for MRD can detect even 1 cancer cell out of 10,000-1,000,000 cells in the bone marrow. Many patients who have been treated with ONCASPAR-containing regimens have reached MRD negativity, making them disease free.

In Dana-Farber Cancer Institute study 11-001, 87.9% of patients treated with ONCASPAR as part of a multicomponent chemotherapy regimen were MRD negative by the end of the induction phase (first phase) of the treatment.

MRD Negative

87.9% of patients treated with ONCASPAR achieved MRD negativity by the end of induction.

All preferred regimens for frontline therapy for AYA patients with Ph-negative ALL in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) contain pegaspargase (ONCASPAR).

Read about ONCASPAR’s well-established safety profile

LEARN MORE
An acute lymphoblastic leukemia patient poses with their hand on their chin.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION Section

ONCASPAR should not be given to patients who have had:

  • Serious allergic reactions to ONCASPAR (pegaspargase) or any of its ingredients
  • Serious blood clots, serious swelling of the pancreas (abdominal pain), or serious bleeding during previous L-asparaginase treatment
  • Serious impairment of liver function

IMPORTANT SAFETY INFORMATION

ONCASPAR should not be given to patients who have had:

  • Serious allergic reactions to ONCASPAR (pegaspargase) or any of its ingredients
  • Serious blood clots, serious swelling of the pancreas (abdominal pain), or serious bleeding during previous L-asparaginase treatment
  • Serious impairment of liver function

ONCASPAR may cause serious side effects including:

  • Allergic reactions (Symptoms: hives and itching, a swollen tongue or throat, trouble breathing, dizziness, fainting)
  • Swelling of the pancreas (Symptoms: severe stomach pain, nausea, vomiting, fever, chills, diarrhea)
  • Blood clots (Symptoms: severe headache, arm or leg swelling, shortness of breath, chest pain)
  • Increased/excess sugar in the blood (Symptoms: Excessive thirst, increased amount of urine or urinary frequency)
  • Unusual bleeding or bruising
  • Abnormal liver function or damage (Symptoms: jaundice, severe nausea, vomiting)

Call or see your doctor right away if you develop any of these serious side effects or if symptoms get worse.

Before receiving ONCASPAR, tell your doctor about all your medical conditions, including if you:

  • are pregnant or plan to become pregnant. ONCASPAR can harm your unborn baby. You should not become pregnant during treatment with ONCASPAR. Tell your doctor right away if you become pregnant or think you may be pregnant during treatment with ONCASPAR.
  • Females who are able to become pregnant: You should use effective non-hormonal birth control (contraception) during treatment with ONCASPAR and for at least 3 months after the last dose.
  • are breastfeeding or plan to breastfeed. It is not known if ONCASPAR passes into your breast milk. Do not breastfeed during treatment with ONCASPAR and for 1 month after your last dose.

How will I receive ONCASPAR?

  • ONCASPAR will be given to you as an injection by your doctor as part of your chemotherapy treatment plan. It is important that you receive all of your treatment doses according to your doctor’s instructions.
  • During treatment, you will be monitored, and if you experience side effects, your doctor may have to change your treatment.

The most common side effects of ONCASPAR include: low albumin blood level (hypoalbuminemia), elevated liver enzymes, fever with low white blood cell count, abnormal elevation of triglyceride levels in the blood (hypertriglyceridemia), a high level of blood sugar (hyperglycemia), increased bilirubin level, swelling of the pancreas, abnormal clotting studies, embolic and thrombotic events, allergic reactions, sepsis, and infections.

This is not a complete list of side effects that may occur. Call your doctor for medical advice about any side effects especially if they do not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit

, or call 1-800-FDA-1088. You may also report side effects to Servier Pharmaceuticals LLC at 1-800-807-6124.

For additional information, please refer to the ONCASPAR Full Prescribing Information and discuss any questions with your doctor.

ONCASPAR is a registered trademark of Servier IP UK Ltd., a wholly-owned, indirect subsidiary of Les Laboratoires Servier. Servier and the Servier logo are registered trademarks of Les Laboratoires Servier.